HENRY SCHEIN
NEWS RELEASE
Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747
FOR IMMEDIATE RELEASE
HENRY SCHEIN REPORTS RECORD SECOND QUARTER RESULTS
Sales increase 19% to $1.6 billion
Diluted EPS from continuing operations up 18% to $0.71
MELVILLE, N.Y. - August 5, 2008 - Henry Schein, Inc. (NASDAQ: HSIC), the largest
provider of healthcare products and services to office-based practitioners in
the combined North American and European markets, today reported record
financial results for the quarter ended June 28, 2008.
Net sales for the second quarter of 2008 were $1.6 billion, an increase
of 18.6% compared with the second quarter of 2007. This increase includes 13.6%
local currency growth (4.0% internally generated and 9.6% from acquisitions) and
5.0% related to foreign currency exchange. (See Exhibit A for details of sales
growth.) The Company previously announced an initiative of reducing sales of
certain lower-margin pharmaceutical products. Excluding sales of those
products, internal net sales growth in local currencies was 6.6%.
Income from continuing operations for the second quarter of 2008 was
$65.5 million, or $0.71 per diluted share, up 20.3% and 18.3%, respectively,
compared with the prior-year second quarter. There was no impact from
discontinued operations on our 2008 results.
"Second quarter financial results reflect a strong contribution from
our International Group, as well as solid growth in our Dental Group," said
Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein.
"These results illustrate Henry Schein's ability to deliver consistent sales and
earnings growth."
Dental Group sales of $660 million increased 9.7%, including 8.7%
growth in local currencies (7.2% internally generated and 1.5% from
acquisitions) and 1.0% growth related to foreign currency exchange. Of the 8.7%
local currency growth, Dental consumable merchandise sales increased 7.9% (6.3%
internal growth and 1.6% acquisition growth) and Dental equipment sales and
service revenues were up 11.0% (9.9% internal growth and 1.1% acquisition
growth).
"Our Dental Group continues to gain market share in consumable
merchandise and in equipment," commented Mr. Bergman. "We recorded another
quarter of double-digit growth in equipment sales and service revenues,
highlighted by gains in high-tech products, including acceleration in sales of
the E4D CAD/CAM product compared with the first quarter."
Medical Group sales of $329 million declined 8.3% (8.9% decline in
internal growth and 0.6% acquisition growth). Excluding sales of certain lower-
margin pharmaceutical products, noted above, internal Medical Group net sales
growth was approximately 1%.
"With the progress we have made under the Medical One World initiative,
coupled with the growth we have seen in Privileges enrollment, we look forward
to capitalizing on future sales growth opportunities within our Medical Group,"
said Mr. Bergman. "We are also optimistic about the upcoming influenza vaccine
season, based on current market conditions and customer order activity."
For the quarter, International Group sales of $615 million increased
55.7%, including 39.7% growth in local currencies (10.9% internally generated
and 28.8% from acquisitions) and 16.0% related to foreign currency exchange.
"Our International Group reported strong growth in all major markets,
highlighted by solid Dental growth," added Mr. Bergman. "We are also pleased to
report that W. & J. Dunlop continues to perform above expectations."
Technology and Value-Added Services Group sales of $41 million
increased 29.0%, including 28.6% growth in local currencies (1.8% internally
generated and 26.8% acquisition growth) and 0.4% growth related to foreign
currency exchange.
"Results reflect good growth in electronic and financial services, as
well as last year's acquisition of Software of Excellence, a leading supplier of
innovative clinical and practice management solutions to dentists," stated Mr.
Bergman. "During the second quarter we launched Easy Dental 2008, offering
dentists increased functionality and improved productivity."
Year-to-Date Results
For the first six months of 2008, net sales of $3.2 billion represent
an increase of 17.6% compared with the first six months of 2007. This increase
includes 12.8% local currency growth (3.5% internally generated and 9.3% from
acquisitions) and 4.8% related to foreign currency exchange. Excluding sales of
certain lower-margin pharmaceutical products, noted above, internal net sales
growth was 6.0%. Income from continuing operations for the first six months of
2008 was $117.8 million, reflecting 20.4% growth compared with the prior year.
Earnings per diluted share from continuing operations of $1.28 for the first six
months of 2008 represents 18.5% growth over the comparable period in 2007.
2
-more-
Stock Repurchase Plan
Henry Schein announced that it repurchased 602,000 shares of common
stock during the second quarter of 2008 for a total purchase price of nearly
$32 million. Approximately $109 million remains authorized for future common
stock repurchases. The impact of the share repurchases during the quarter was
immaterial to diluted EPS.
2008 EPS Guidance
Henry Schein affirms 2008 financial guidance, as follows:
o 2008 diluted EPS is expected to be $2.93 to $3.00, representing growth
of 14% to 16% compared with 2007.
o This 2008 diluted EPS guidance includes Henry Schein's expectation that
it will distribute 12 million to 15 million doses of influenza vaccine
during the year, representing earnings of $0.13 to $0.16 per diluted
share.
o 2008 diluted EPS guidance is for current continuing operations
including completed or previously announced acquisitions, and does not
include the impact of potential future acquisitions, if any.
Second Quarter Conference Call Webcast
The Company will hold a conference call to discuss second quarter
financial results today, beginning at 10:00 a.m. Eastern time. Individual
investors are invited to listen to the conference call over the Internet through
Henry Schein's Web site at www.henryschein.com. In addition, a replay will be
available beginning shortly after the call has ended.
About Henry Schein
Henry Schein, a Fortune 500(R) company and a member of the NASDAQ
100(R) Index, is recognized for its excellent customer service and highly
competitive prices. The Company's four business groups - Dental, Medical,
International and Technology - serve more than 550,000 customers worldwide,
including dental practitioners and laboratories, physician practices and animal
health clinics, as well as government and other institutions.
3
- more -
The Company operates through a centralized and automated distribution
network, which provides customers in more than 200 countries with a
comprehensive selection of more than 90,000 national and Henry Schein private-
brand products in stock, as well as more than 100,000 additional products
available as special-order items.
Henry Schein also offers a wide range of innovative value-added
practice solutions for healthcare professionals, such as ArubA(R), the Company's
electronic catalog and ordering system. Its leading practice-management
software solutions have an installed user base of more than 52,000 practices,
including DENTRIX(R), Easy Dental(R), Oasis(R) and EXACT(R) for dental
practices, MicroMD(R) for physician practices, and AVImark(R) for animal health
clinics.
Headquartered in Melville, N.Y., Henry Schein employs over 12,000
people and has operations or affiliates in 20 countries. The Company's net
sales reached a record $5.9 billion in 2007. For more information, visit the
Henry Schein Web site at www.henryschein.com.
In accordance with the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995, we provide the following cautionary remarks
regarding important factors that, among others, could cause future results to
differ materially from the forward-looking statements, expectations and
assumptions expressed or implied herein. All forward-looking statements made by
us are subject to risks and uncertainties and are not guarantees of future
performance. These forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance
and achievements or industry results to be materially different from any future
results, performance or achievements expressed or implied by such forward-
looking statements. These statements are identified by the use of such terms as
"may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast,"
"project," "anticipate" or other comparable terms. A full discussion of our
operations and financial condition, including factors that may affect our
business and future prospects, is contained in documents we have filed with the
SEC and will be contained in all subsequent periodic filings we make with the
SEC. These documents identify in detail important risk factors that could cause
our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ
materially from current and historical results include, but are not limited to:
competitive factors; changes in the healthcare industry; changes in regulatory
requirements that affect us; risks associated with our international operations;
fluctuations in quarterly earnings; our dependence on third parties for the
manufacture and supply of our products; transitional challenges associated with
acquisitions, including the failure to achieve anticipated synergies; financial
risks associated with acquisitions; regulatory and litigation risks; the
dependence on our continued product development, technical support and
successful marketing in the technology segment; our dependence upon sales
personnel and key customers; our dependence on our senior management; possible
increases in the cost of shipping our products or other service trouble with our
third-party shippers; risks from rapid technological change; risks from
potential increases in variable interest rates; possible volatility of the
market price of our common stock; certain provisions in our governing documents
that may discourage third-party acquisitions of us; and changes in tax
legislation that affect us. The order in which these factors appear should not
be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these
factors are beyond our ability to control or predict. Accordingly, any forward-
looking statements contained herein should not be relied upon as a prediction of
actual results. We undertake no duty and have no obligation to update forward-
looking statements.
4
- more -
(TABLES TO FOLLOW)
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
----------------------------- -----------------------------
June 28, June 30, June 28, June 30,
2008 2007 2008 2007
------------- ------------- ------------- -------------
Net sales .................................................... $ 1,644,977 $ 1,387,017 $ 3,170,596 $ 2,697,145
Cost of sales ................................................ 1,156,562 973,240 2,230,948 1,892,322
------------- ------------- ------------- -------------
Gross profit .......................................... 488,415 413,777 939,648 804,823
Operating expenses:
Selling, general and administrative ...................... 375,058 322,925 741,064 640,250
------------- ------------- ------------- -------------
Operating income ...................................... 113,357 90,852 198,584 164,573
Other income (expense):
Interest income .......................................... 3,974 4,269 7,957 8,388
Interest expense ......................................... (8,205) (6,223) (15,107) (12,165)
Other, net ............................................... (291) 547 (674) 425
------------- ------------- ------------- -------------
Income from continuing operations before
taxes, minority interest and equity in
earnings (losses) of affiliates ...................... 108,835 89,445 190,760 161,221
Income taxes ................................................. (37,135) (30,636) (64,990) (56,106)
Minority interest in net income of subsidiaries .............. (7,131) (3,842) (10,381) (6,757)
Equity in earnings (losses) of affiliates .................... 908 (528) 2,418 (505)
------------- ------------- ------------- -------------
Income from continuing operations ............................ 65,477 54,439 117,807 97,853
Discontinued operations:
Loss from operations of discontinued
components (including write-down of long-lived
assets of $32.7 million) ............................... -- (32,700) -- (32,560)
Income tax benefit ....................................... -- 12,098 -- 12,038
------------- ------------- ------------- -------------
Loss from discontinued operations ........................ -- (20,602) -- (20,522)
------------- ------------- ------------- -------------
Net income ................................................... $ 65,477 $ 33,837 $ 117,807 $ 77,331
============= ============= ============= =============
Earnings from continuing operations per share:
Basic .................................................... $ 0.73 $ 0.62 $ 1.32 $ 1.11
============= ============= ============= =============
Diluted .................................................. $ 0.71 $ 0.60 $ 1.28 $ 1.08
============= ============= ============= =============
Loss from discontinued operations per share:
Basic .................................................... $ -- $ (0.24) $ -- $ (0.23)
============= ============= ============= =============
Diluted .................................................. $ -- $ (0.23) $ -- $ (0.22)
============= ============= ============= =============
Earnings per share:
Basic .................................................... $ 0.73 $ 0.38 $ 1.32 $ 0.88
============= ============= ============= =============
Diluted .................................................. $ 0.71 $ 0.37 $ 1.28 $ 0.86
============= ============= ============= =============
Weighted-average common shares outstanding:
Basic .................................................... 89,587 88,390 89,417 88,154
============= ============= ============= =============
Diluted .................................................. 92,012 90,591 92,212 90,344
============= ============= ============= =============
5
- more -
HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
June 28, December 29,
2008 2007
------------- -------------
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents .................................................. $ 271,432 $ 247,590
Available-for-sale securities............................................... 11,925 997
Accounts receivable, net of reserves of $41,472 and $41,315 ................ 731,499 708,307
Inventories, net ........................................................... 693,556 666,786
Deferred income taxes ...................................................... 36,203 32,827
Prepaid expenses and other ................................................. 186,508 192,292
------------- -------------
Total current assets ............................................... 1,931,123 1,848,799
Property and equipment, net .................................................... 254,110 247,671
Goodwill ....................................................................... 954,203 917,194
Other intangibles, net ......................................................... 191,039 192,420
Investments and other .......................................................... 139,040 107,900
------------- -------------
Total assets ....................................................... $ 3,469,515 $ 3,313,984
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ........................................................... $ 453,800 $ 474,009
Bank credit lines .......................................................... 6,207 8,977
Current maturities of long-term debt ....................................... 23,624 24,319
Accrued expenses:
Payroll and related ..................................................... 124,213 136,291
Taxes ................................................................... 87,359 73,278
Other ................................................................... 226,615 223,765
------------- -------------
Total current liabilities .......................................... 921,818 940,639
Long-term debt ................................................................. 424,470 423,274
Deferred income taxes ........................................................... 92,699 80,260
Other liabilities .............................................................. 54,644 53,906
Minority interest .............................................................. 46,816 35,923
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized,
none outstanding ........................................................ -- --
Common stock, $.01 par value, 240,000,000 shares authorized,
89,762,723 outstanding on June 28, 2008 and
89,603,660 outstanding on December 29, 2007 ............................. 898 896
Additional paid-in capital .................................................. 693,133 673,763
Retained earnings ........................................................... 1,103,206 1,005,055
Accumulated other comprehensive income ...................................... 131,831 100,268
------------- -------------
Total stockholders' equity ......................................... 1,929,068 1,779,982
------------- -------------
Total liabilities and stockholders' equity ......................... $ 3,469,515 3,313,984
============= =============
6
- more -
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended
-----------------------------
June 28, June 30,
2008 2007
------------- -------------
Cash flows from operating activities:
Net income ................................................................. $ 65,477 $ 33,837
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization ....................................... 20,270 17,670
Stock-based compensation expense .................................... 6,956 6,608
Impairment from write-down of long-lived assets of
discontinued operations ....................................... -- 32,667
Provision for losses on trade and other accounts receivable ......... 1,467 1
Provision for (benefit from) deferred income taxes .................. 448 (11,833)
Undistributed (earnings) losses of affiliates ....................... (908) 528
Minority interest in net income of subsidiaries ..................... 7,131 3,842
Other ............................................................... (891) 151
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... (23,256) (12,809)
Inventories ................................................... 16,023 11,510
Other current assets .......................................... 8,452 (7,413)
Accounts payable and accrued expenses ......................... 24,108 39,884
------------- -------------
Net cash provided by operating activities ...................................... 125,277 114,643
------------- -------------
Cash flows from investing activities:
Purchases of fixed assets ................................................. (9,723) (12,403)
Payments for equity investment and business acquisitions,
net of cash acquired ................................................... (15,057) (14,391)
Purchases of available-for-sale securities ................................ -- (70,501)
Proceeds from sales of available-for-sale securities ...................... -- 30,000
Net payments for foreign exchange forward contract settlements ............ (3,048) (7,692)
Other ..................................................................... 5,306 653
------------- -------------
Net cash used in investing activities .......................................... (22,522) (74,334)
------------- -------------
Cash flows from financing activities:
Proceeds from issuance of long-term debt .................................. -- 55
Repayments of bank borrowings ............................................. (2,589) (26)
Principal payments for long-term debt ..................................... (4,976) (17,468)
Proceeds from issuance of stock upon exercise of stock options ............ 5,523 12,929
Payments for repurchases of common stock .................................. (31,647) --
Excess tax benefits related to stock-based compensation ................... 1,244 2,169
Other ..................................................................... (977) (721)
------------- -------------
Net cash used in financing activities .......................................... (33,422) (3,062)
------------- -------------
Net change in cash and cash equivalents ........................................ 69,333 37,247
Effect of exchange rate changes on cash and cash equivalents ................... (937) (732)
Cash and cash equivalents, beginning of period ................................. 203,036 154,456
------------- -------------
Cash and cash equivalents, end of period ....................................... $ 271,432 $ 190,971
============= =============
Six Months Ended
-----------------------------
June 28, June 30,
2008 2007
------------- -------------
Cash flows from operating activities:
Net income ................................................................. $ 117,807 $ 77,331
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization ....................................... 39,708 35,227
Stock-based compensation expense .................................... 16,216 10,725
Impairment from write-down of long-lived assets of
discontinued operations ....................................... -- 32,667
Provision for losses on trade and other accounts receivable ......... 2,604 232
Provision for (benefit from) deferred income taxes .................. (2,891) (18,688)
Undistributed (earnings) losses of affiliates ....................... (2,418) 505
Minority interest in net income of subsidiaries ..................... 10,381 6,757
Other ............................................................... (1,317) (570)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... (6,752) (16,756)
Inventories ................................................... (5,064) 15,446
Other current assets .......................................... 10,955 4,469
Accounts payable and accrued expenses ......................... (40,612) (66,604)
------------- -------------
Net cash provided by operating activities ...................................... 138,617 80,741
------------- -------------
Cash flows from investing activities:
Purchases of fixed assets ................................................. (23,466) (21,336)
Payments for equity investment and business acquisitions,
net of cash acquired ................................................... (23,581) (41,823)
Purchases of available-for-sale securities ................................ (35,925) (88,001)
Proceeds from sales of available-for-sale securities ...................... 847 48,000
Net payments for foreign exchange forward contract settlements ............ (5,052) (11,613)
Other ..................................................................... 4,571 (4,609)
------------- -------------
Net cash used in investing activities .......................................... (82,606) (119,382)
------------- -------------
Cash flows from financing activities:
Proceeds from issuance of long-term debt .................................. -- 483
Repayments of bank borrowings ............................................. (6,508) (281)
Principal payments for long-term debt ..................................... (5,949) (17,925)
Proceeds from issuance of stock upon exercise of stock options ............ 12,695 23,620
Payments for repurchases of common stock .................................. (31,647) (30,689)
Excess tax benefits related to stock-based compensation ................... 4,673 8,022
Other ..................................................................... (1,401) (1,457)
------------- -------------
Net cash used in financing activities .......................................... (28,137) (18,227)
------------- -------------
Net change in cash and cash equivalents ........................................ 27,874 (56,868)
Effect of exchange rate changes on cash and cash equivalents ................... (4,032) (808)
Cash and cash equivalents, beginning of period ................................. 247,590 248,647
------------- -------------
Cash and cash equivalents, end of period ....................................... $ 271,432 $ 190,971
============= =============
7
- more -
Exhibit A
Henry Schein, Inc.
2008 Second Quarter
Sales Growth Rate Summary
(unaudited)
Q2 2008 over Q2 2007
--------------------
Consolidated Dental Medical International Technology
------------ ----------- ------------ ------------- ------------
Internal Sales Growth 4.0% 7.2% -8.9% 10.9% 1.8%
Acquisitions 9.6% 1.5% 0.6% 28.8% 26.8%
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth 13.6% 8.7% -8.3% 39.7% 28.6%
Foreign Currency Exchange 5.0% 1.0% -- 16.0% 0.4%
------------ ----------- ------------ ------------- ------------
Total Sales Growth 18.6% 9.7% -8.3% 55.7% 29.0%
============ =========== ============ ============= ============
Q2 YTD 2008 over Q2 YTD 2007
----------------------------
Consolidated Dental Medical International Technology
------------ ----------- ------------ ------------- ------------
Internal Sales Growth 3.5% 6.4% -6.7% 8.3% 5.9%
Acquisitions 9.3% 1.6% 0.7% 27.7% 26.2%
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth 12.8% 8.0% -6.0% 36.0% 32.1%
Foreign Currency Exchange 4.8% 1.2% -- 14.8% 0.4%
------------ ----------- ------------ ------------- ------------
Total Sales Growth 17.6% 9.2% -6.0% 50.8% 32.5%
============ =========== ============ ============= ============
CONTACTS: Steven Paladino
Executive Vice President and Chief Financial Officer
steven.paladino@henryschein.com
(631) 843-5500
Investors: Neal Goldner
Vice President, Investor Relations
neal.goldner@henryschein.com
(631) 845-2820
Media: Susan Vassallo
Vice President, Corporate Communications
susan.vassallo@henryschein.com
(631) 843-5562
8
###